{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:00:57Z","timestamp":1771660857448,"version":"3.50.1"},"reference-count":41,"publisher":"Akademiai Kiado Zrt.","issue":"8","license":[{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2022,2,20]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> A palliat\u00edv ell\u00e1t\u00e1s c\u00e9lja a beteg \u00e9s csal\u00e1dja\n                    \u00e9letmin\u0151s\u00e9g\u00e9nek jav\u00edt\u00e1sa egy \u00e9letet megr\u00f6vid\u00edt\u0151 betegs\u00e9g sor\u00e1n. A palliat\u00edv\n                    betegpopul\u00e1ci\u00f3 32\u201380%-a kap sziszt\u00e9m\u00e1s szteroidot k\u00ednz\u00f3 t\u00fcnetek enyh\u00edt\u00e9s\u00e9re. Az\n                    alkalmaz\u00e1si ir\u00e1nyelvek, a szteroidhaszn\u00e1lat a palliat\u00edv betegek k\u00f6r\u00e9ben nagyon\n                    v\u00e1ltoz\u00f3 az egyes orsz\u00e1gok, de az orsz\u00e1gon bel\u00fcli ell\u00e1t\u00f3k k\u00f6z\u00f6tt is. A palliat\u00edv\n                    betegell\u00e1t\u00e1sban szteroidokat \u2013 els\u0151sorban sziszt\u00e9m\u00e1s gl\u00fckokortikoidokat\n                    (dexametazon, betametazon, prednizolon, metilprednizolon) \u2013 f\u0151leg\n                    antiinflammatorikus \u00e9s a vascularis permeabilit\u00e1st cs\u00f6kkent\u0151 hat\u00e1suk miatt\n                    alkalmazunk. A palliat\u00edv ell\u00e1t\u00e1s sor\u00e1n gl\u00fckokortikoid ad\u00e1sa sz\u00e1mos specifikus\n                    indik\u00e1ci\u00f3 eset\u00e9n javasolhat\u00f3, mint idegi kompresszi\u00f3, neuropathi\u00e1s f\u00e1jdalom,\n                    csontf\u00e1jdalom \u00e9s metastasis, m\u00e1jtokfesz\u00fcl\u00e9s okozta f\u00e1jdalom, malignus\n                    b\u00e9lobstrukci\u00f3, agynyom\u00e1s-fokoz\u00f3d\u00e1s, malignus gerincvel\u0151-kompresszi\u00f3, vena cava\n                    superior szindr\u00f3ma, lymphangitis carcinomatosa, nagy l\u00e9g\u00fati obstrukci\u00f3. Sokszor\n                    p\u00e1rhuzamosan jelentkez\u0151, nem specifikus t\u00fcnetek \u2013 mint anorexia-cachexia\n                    szindr\u00f3ma, h\u00e1nyinger, h\u00e1ny\u00e1s, f\u00e1radts\u00e1g, gyenges\u00e9g, neh\u00e9zl\u00e9gz\u00e9s \u2013 szint\u00e9n\n                    sz\u00fcks\u00e9gess\u00e9 tehetik szteroid ad\u00e1s\u00e1t. A palliat\u00edv betegek progn\u00f3zis\u00e1t figyelembe\n                    v\u00e9ve a szteroidok k\u00e9s\u0151i mell\u00e9khat\u00e1sai nem korl\u00e1tozz\u00e1k ad\u00e1sukat, az els\u0151dleges\n                    ter\u00e1pi\u00e1s el\u0151ny fel\u00fclm\u00falja a lehets\u00e9ges kock\u00e1zatokat. A nemzetk\u00f6zi gyakorlatban a\n                    dexametazon a leggyakrabban alkalmazott gl\u00fckokortikoid, kifejezett\n                    gyullad\u00e1scs\u00f6kkent\u0151 hat\u00e1sa \u00e9s kevesebb mineralokortikoid-mell\u00e9khat\u00e1sa miatt.\n                    Fontos, elengedhetetlen r\u00e9sze a biztons\u00e1gos szteroidter\u00e1pi\u00e1nak a mell\u00e9khat\u00e1sok\n                    gondos monitoroz\u00e1sa, err\u0151l a beteget \u00e9s a hozz\u00e1tartoz\u00f3kat is fel kell\n                    vil\u00e1gos\u00edtani. A megfelel\u0151 indik\u00e1ci\u00f3ban, d\u00f3zisban \u00e9s megfelel\u0151 kezel\u00e9si terv\n                    alapj\u00e1n adagolt szteroid hasznos r\u00e9sze a palliat\u00edv t\u00fcnetkontrollnak, a beteg\n                    \u00e9letmin\u0151s\u00e9g-jav\u00edt\u00e1s\u00e1nak. Orv Hetil. 2022; 163(8): 294\u2013300.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> Palliative care aims to improve the quality of life of\n                    patients and their families during a life-shortening illness. 32\u201380% of the\n                    palliative patient population receive systemic steroids to relieve torturous\n                    symptoms during end-of-life care. Guidelines for steroid use among palliative\n                    patients vary widely from country to country, but also within providers. In\n                    palliative care, steroids \u2013 mainly systemic glucocorticoids (dexamethasone,\n                    betamethasone, prednisolone, methylprednisolone) \u2013 are used especially for their\n                    anti-inflammatory and vascular permeability-reducing effects. Glucocorticoid\n                    administration during palliative care is recommended for a number of specific\n                    indications, such as neural compression, neuropathic pain, bone pain and\n                    metastasis, liver capsule pain, malignant intestinal obstruction, increased\n                    cerebral pressure, malignant spinal cord compression, superior vena cava\n                    syndrome, carcinomatous lymphangitis, and large airway compression. Often\n                    concomitant non-specific symptoms such as anorexia-cachexia syndrome, nausea,\n                    vomiting, fatigue, weakness, dyspnoea may also necessitate steroid\n                    administration. Considering the prognosis of palliative patients, the late side\n                    effects of steroids do not limit their administration, the primary therapeutic\n                    benefit outweighs the potential risks. Internationally, dexamethasone is the\n                    most commonly used glucocorticoid due to its pronounced anti-inflammatory effect\n                    and fewer mineralocorticoid side effects. Careful monitoring of side effects is\n                    an important and essential part of safe steroid therapy and should be made clear\n                    to the patient and their relatives. Steroids administered in the right\n                    indication and dose as well as according to an appropriate treatment plan are\n                    useful parts of palliative symptom control and improve patients\u2019 quality of\n                    life. Orv Hetil. 2022; 163(8): 294\u2013300.<\/jats:p>","DOI":"10.1556\/650.2022.32374","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T21:00:51Z","timestamp":1668805251000},"page":"294-300","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":5,"title":["Szteroidok gyakorlati alkalmaz\u00e1sa a palliat\u00edv ter\u00e1pi\u00e1ban"],"prefix":"10.1556","volume":"163","author":[{"given":"N\u00f3ra","family":"Frank","sequence":"first","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Alapell\u00e1t\u00e1si Int\u00e9zet, Hospice-Palliat\u00edv Tansz\u00e9k P\u00e9cs, R\u00e1k\u00f3czi \u00fat 2., 7623 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"Csik\u00f3s","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Alapell\u00e1t\u00e1si Int\u00e9zet, Hospice-Palliat\u00edv Tansz\u00e9k P\u00e9cs, R\u00e1k\u00f3czi \u00fat 2., 7623 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jpainsymman.2020.04.027","article-title":"Redefining palliative care - a new consensus-based definition","volume":"60","author":"1 Radbruch","year":"2020","unstructured":"1 Radbruch L, De Lima L, Knaul F, et al. Redefining palliative care - a new consensus-based definition. J Pain Symptom Manage 2020; 60: 754-764.","journal-title":"J Pain Symptom Manage"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"2 Temel","year":"2010","unstructured":"2 Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363: 733-742.","journal-title":"N Engl J Med"},{"key":"ref2","unstructured":"3 Beny\u00f3 G, Luk\u00e1cs M, Busa Cs, et al. Current situation of palliative care in Hungary. Integrated palliative care model as a breakout possibiliy. [A magyarorsz\u00e1gi palliat\u00edv-hospice ell\u00e1t\u00e1s helyzete, kih\u00edv\u00e1sai, kit\u00f6r\u00e9si pontjai.] Magy Onkol. 2017; 61: 292-299. [Hungarian]"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4 Heged\u0171s K, Luk\u00e1cs M, Schaffer J. Situation, possibilities and difficulties of the hospice and palliative care in Hungary. [A hazai hospice- \u00e9s palliat\u00edv ell\u00e1t\u00e1s helyzet, lehet\u0151s\u00e9gei, neh\u00e9zs\u00e9gei.] Orv Hetil. 2014; 155: 1504-1509. [Hungarian]","DOI":"10.1556\/OH.2014.29995"},{"key":"ref4","unstructured":"5 European Association for Palliative Care (EAPC). What is palliative care? Available from: https:\/\/www.eapcnet.eu\/about-us\/what-we-do\/ [accessed: May 5, 2021]."},{"key":"ref5","unstructured":"6 European Association for Palliative Care (EAPC) update. White paper on standards and norms for hospice and palliative care in Europe: part 1. Recommendations from the European Association for Palliative Care. Eur J Palliat Care 2009; 16: 278-289. Available from: https:\/\/eapcresearchcongress2020.eu\/wp-content\/uploads\/2020\/11\/White-Paper-on-standards-and-norms-for-hospice-and-palliative-care-in-Europe.pdf [accessed: May 5, 2021]."},{"key":"ref6","unstructured":"7 Worldwide Palliative Care Alliance and World Health Organization. Global atlas of palliative care at the end of life. WHO, Geneva, 2014. Available from: https:\/\/www.who.int\/nmh\/Global_Atlas_of_Palliative_Care.pdf [accessed: Dec 12, 2020]."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-684X-13-7","article-title":"Corticosteroid prescribing in palliative care settings: a retrospective analysis in New Zealand","volume":"13","author":"Denton A","year":"2014","unstructured":"8 Denton A, Shaw J. Corticosteroid prescribing in palliative care settings: a retrospective analysis in New Zealand. BMC Palliat Care 2014; 13: 7.","journal-title":"BMC Palliat Care"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1472-684X-13-50","article-title":"Corticosteroids in palliative care - perspectives of clinicians involved in prescribing: a qualitative study","volume":"13","author":"Denton A","year":"2014","unstructured":"9 Denton A, Shaw J. Corticosteroids in palliative care - perspectives of clinicians involved in prescribing: a qualitative study. BMC Palliat Care 2014; 13: 50.","journal-title":"BMC Palliat Care"},{"key":"ref9","unstructured":"10 Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985; 69: 751-754."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S0885-3924(02)00487-6","article-title":"A retrospective observation of corticosteroid use at the end of life in a hospice","volume":"24","author":"Gannon C","year":"2002","unstructured":"11 Gannon C, McNamara P. A retrospective observation of corticosteroid use at the end of life in a hospice. J Pain Symptom Manage 2002; 24: 328-334.","journal-title":"J Pain Symptom Manage"},{"key":"ref11","unstructured":"12 T\u00edm\u00e1r J. Adrenal hormones. Synthetic corticosteroids. Antagonists of adrenal hormones and inhibitors of synthesis. In: F\u00fcrst Zs. (ed.) Pharmacology. [Mell\u00e9kvesek\u00e9reg-hormonok. Szintetikus kortikoszteroidok. A mell\u00e9kvesek\u00e9reg-hormonok antagonist\u00e1i \u00e9s szint\u00e9zis g\u00e1tl\u00f3i. In: F\u00fcrst Zs. (szerk.) Farmakol\u00f3gia.] Medicina K\u00f6nyvkiad\u00f3, Budapest, 2001; pp. 826-842. [Hungarian]"},{"key":"ref12","unstructured":"13 Joint British Diabetes Societies for inpatient care (JBDS-IP). Management of hyperglycaemia and steroid (glucocorticoid) therapy. Diabetes UK, London, 2014. Available from: https:\/\/www.diabetes.org.uk\/resources-s3\/2017-09\/JBDS%20management%20of%20hyperglycaemia%20and%20steriod%20therapy_0.pdf [accessed: May 5, 2021]."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/0885-3924(94)90200-3","article-title":"Corticosteroids as adjuvant analgesics","volume":"9","author":"Watanabe S","year":"1994","unstructured":"14 Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 1994; 9: 442-445.","journal-title":"J Pain Symptom Manage"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11916-012-0273-z","article-title":"The role of corticosteroids in the treatment of pain in cancer patients","volume":"16","author":"Leppert W","year":"2012","unstructured":"15 Leppert W, Buss T. The role of corticosteroids in the treatment of pain in cancer patients. Curr Pain Headache Rep. 2012; 16: 307-313.","journal-title":"Curr Pain Headache Rep"},{"key":"ref15","unstructured":"16 Husbands E. Use of corticosteroids. St Michael's Hospice, clinical care guidelines. 2006. Available from: https:\/\/www.palliativedrugs.com\/download\/steroidguidelines.pdf [accessed: Jan 5, 2021]."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1089\/jpm.2020.0181","article-title":"Corticosteroids for common palliative care symptoms #395","volume":"23","author":"17 Cardenas-Mori","year":"2020","unstructured":"17 Cardenas-Mori J, Lewis-Ramos V. Corticosteroids for common palliative care symptoms #395. J Palliat Med. 2020; 23: 987-989.","journal-title":"J Palliat Med"},{"key":"ref17","unstructured":"18 Fletcher A, Murray A. Guidelines for use of steroids in cancer patients. Wigan and Leigh hospice. 2009. Available from: https:\/\/www.researchgate.net\/profile\/Ali_Aldallal2\/post\/How_often_do_you_experience_systemic_side_effects_of_glucocorticoids_using_eye_drops_with_dexamethasone\/attachment\/59d625a379197b8077983f61\/AS%3A318546062577664%401452958707609\/download\/GUIDELINES_FOR_USE_OF_STEROIDS_IN_CANCER_PATIENTS.pdf [accessed: April 3, 2021]."},{"key":"ref18","unstructured":"19 Gough L. Use of steroids in palliative care. Guideline of Hospice in the Weald. September 2013. Available from: https:\/\/www.academia.edu\/11937987\/Guideline_Use_of_Steroids_in_Palliative_Care [accessed: May 05, 2021]."},{"key":"ref19","unstructured":"20 The Princess Alice Hospice. Guidelines for corticosteroid use in palliative care. Steroid guidelines, 2008. Available from: https:\/\/www.palliativedrugs.com\/download\/090423_Steroid_Guidelines_Summary_2008.pdf [accessed: March 26, 2021]."},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21 Radv\u00e1nyi I, Nagy L, Balogh S, et al. Palliative care in non-cancer chronic progressive diseases. [Nem daganatos, kr\u00f3nikus progressz\u00edv betegs\u00e9gek palliat\u00edv ell\u00e1t\u00e1sa.] Orv Hetil. 2015; 156: 1703-1709. [Hungarian]","DOI":"10.1556\/650.2015.30272"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1191\/026921601673324846","article-title":"A prospective survey of the use of dexamethasone on a palliative care unit","volume":"15","author":"22 Hardy","year":"2001","unstructured":"22 Hardy JR, Rees E, Ling J, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med. 2001; 15: 3-8.","journal-title":"Palliat Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1080\/02841860500401167","article-title":"The use of corticosteroids in Swedish palliative care","volume":"45","author":"23 Lundstr\u00f6m","year":"2006","unstructured":"23 Lundstr\u00f6m SH, F\u00fcrst CJ. The use of corticosteroids in Swedish palliative care. Acta Oncol. 2006; 45: 430-437.","journal-title":"Acta Oncol"},{"key":"ref23","unstructured":"24 World Health Organization. Cancer pain relief. 2nd edition. WHO, Geneva, 1996. Available from: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/37896\/9241544821.pdf;jsessionid=2F275A75EE686B31E72AF30AFD3FE15A?sequence=1 [accessed: Feb 2, 2021]."},{"key":"ref24","unstructured":"25 Professional guidelines of the Ministry of Human Resources for the full hospice and palliative care of adult cancer patients. E\u00fcK. 2017; 15. Professional guidelines. [Az Emberi Er\u0151forr\u00e1sok Miniszt\u00e9riuma szakmai ir\u00e1nyelve a daganatos feln\u0151tt betegek teljes k\u00f6r\u0171 hospice \u00e9s palliat\u00edv ell\u00e1t\u00e1s\u00e1r\u00f3l (hat\u00e1lyos: 2017.10.04-) 2017. E\u00fcK. 15. sz\u00e1m EMMI szakmai ir\u00e1nyelv.] Available from: http:\/\/www.hbcs.hu\/uploads\/jogszabaly\/2578\/fajlok\/EEMI_szakmai_iranyelve_daganatos.pdf [accessed: Apr 4, 2021]. [Hungarian]"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26 K\u00fcronya Zs, G\u00e9czi L, Gyergyay F, et al. The role of steroids in oncological practice. [Szteroidok szerepe az onkol\u00f3giai gyakorlatban.] Orv Hetil. 2017; 158: 1651-1657. [Hungarian]","DOI":"10.1556\/650.2017.30879"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/1049909116683720","article-title":"The use of corticosteroids as adjuvant therapy for painful bone metastases: a large cross-sectional survey of palliative care providers","volume":"35","author":"27 White","year":"2018","unstructured":"27 White P, Arnold R, Bull J, et al. The use of corticosteroids as adjuvant therapy for painful bone metastases: a large cross-sectional survey of palliative care providers. Am J Hosp Palliat Care 2018; 35: 151-158.","journal-title":"Am J Hosp Palliat Care"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28 Vayne-Bossert P, Haywood A, Good P, et al. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochane Database Syst Rev. 2017; 7: CD012002.","DOI":"10.1002\/14651858.CD012002.pub2"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jpainsymman.2006.06.014","article-title":"Medical treatment for inoperable malignant bowel obstruction: a qualitative systemic review","volume":"33","author":"29 Mercandante","year":"2007","unstructured":"29 Mercandante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systemic review. J Pain Symptom Manage 2007; 33: 217-223.","journal-title":"J Pain Symptom Manage"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30 Hui D, Kilgore K, Frisbee-Hume S, et al. Dexamethasone for dyspnoe in cancer patients: a pilot double-blind, randomized, controlled trial. J Pain Symptom Manage 2016; 52: 8-16.e1.","DOI":"10.1016\/j.jpainsymman.2015.10.023"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jpainsymman.2004.01.009","article-title":"Dexamethasone in addition to metoclopramide for chronic nausea in patints with advanced cancer: a randomized controlled trial","volume":"28","author":"31 Bruera","year":"2004","unstructured":"31 Bruera E, Moyano JR, Sala R, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patints with advanced cancer: a randomized controlled trial. J Pain Symptom Manage 2004; 28: 381-388.","journal-title":"J Pain Symptom Manage"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s005200000218","article-title":"The use of corticosteroids in home palliative care","volume":"9","author":"32 Mercandante","year":"2001","unstructured":"32 Mercandante S, Fulfaro F, Casuccio A. The use of corticosteroids in home palliative care. Support Care Cancer 2001; 9: 386-389.","journal-title":"Support Care Cancer"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/bmjspcare-2015-001037","article-title":"Pharmacovigilance in hospice\/palliative care: the net inmediate and short-term effects of dexamethasone for anorexia","volume":"6","author":"33 Hatano","year":"2016","unstructured":"33 Hatano Y, Moroni M, Wilcock A, et al. Pharmacovigilance in hospice\/palliative care: the net inmediate and short-term effects of dexamethasone for anorexia. BMJ Support Palliat Care 2016; 6: 331-337.","journal-title":"BMJ Support Palliat Care"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/0269216307085183","article-title":"Fatigue in palliative care patients - an EAPC approach","volume":"22","author":"34 Radbruch","year":"2008","unstructured":"34 Radbruch L, Strasser F, Elsner F, et al. Fatigue in palliative care patients - an EAPC approach. Palliat Med. 2008; 22: 13-32.","journal-title":"Palliat Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/JCO.2012.44.4661","article-title":"Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer","volume":"31","author":"35 Yennurajalingam","year":"2013","unstructured":"35 Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013; 31: 3076-3082.","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36 Radv\u00e1nyi I, Csik\u00f3s \u00c1, Balogh S. The significance of early diagnosis of cancer-related hypercalcaemia. [Malignit\u00e1shoz t\u00e1rsul\u00f3 hypercalcaemia korai felismer\u00e9s\u00e9nek jelent\u0151s\u00e9ge.] Orv Hetil. 2013; 154: 1367-1373. [Hungarian]","DOI":"10.1556\/OH.2013.29665"},{"key":"ref36","unstructured":"37 Bellieu J, Emms H, Murray A. Guidelines for the use of corticosteroids in palliative care. 2009. Available from : https:\/\/www.nwcscnsenate.nhs.uk\/files\/2814\/3394\/6186\/Corticosterioids.pdf [accessed: March 26, 2021]."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/17571472.2015.1082344","article-title":"Steroid-induced hyperglycaemia in primary care","volume":"7","author":"Mills E","year":"2015","unstructured":"38 Mills E, Devendra S. Steroid-induced hyperglycaemia in primary care. London J Prim Care (Abingdon) 2015; 7: 103-106.","journal-title":"London J Prim Care (Abingdon)"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39 Vilder J, Rogers C, Yallop D, et al. Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoploriferative disorders treated with intermittent high dose steroids. J Clin Transl Endocrinol. 2017; 9: 18-20.","DOI":"10.1016\/j.jcte.2017.06.003"},{"key":"ref39","unstructured":"40 Diabetes UK. End of life diabetes care: clinical care recommendations. 3rd edition. 2018. Available from: https:\/\/www.diabetes.org.uk\/resources-s3\/2018-03\/EoL_Guidance_2018_Final.pdf [accessed: Feb 5, 2021]."},{"key":"ref40","unstructured":"41 Lengyel Z, Bo\u00e9r K, Hal\u00e1szlaki Cs, et al. Diabetes in patients with maligmant tumors. [Diabetes daganatos betegs\u00e9gben.] Magy Oncol. 2013; 57: 177-181. [Hungarian]"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/8\/article-p294.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/8\/article-p294.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/8\/article-p294.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T09:39:14Z","timestamp":1698226754000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/8\/article-p294.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,20]]},"references-count":41,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.1556\/650.2022.32374","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,20]]}}}